Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)

Patel, Sapna; Milhem, Mohammed; Hallmeyer, Sigrun; Daniels, Gregory; Cranmer, Lee; Taback, Bret; Flaherty, Lawrence; Aung, Sandra; Lowder, James; Sharfman, William

doi:10.1186/2051-1426-2-S3-P78

Article metrics
Last updated: Fri, 26 Apr 2024 6:53:39 Z

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin^® (HD IL-2) and Ipilimumab Yervoy^® ) in patients with metastatic melanoma (proclivity 02)

Access & Citations

763

Article Accesses
0

Web of Science
0

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.